User:Mr. Ibrahem/Rasagiline
From Wikipedia, the free encyclopedia
Rasagiline, sold under the brand name Azilect among others, is a medication used to treat symptoms in Parkinson's disease.[2] It may be used alone or together with other medication.[2] It is taken by mouth.[2]
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Azilect, Azipron, others |
Other names | VP-1012, N-propargyl-1(R)-aminoindan[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606017 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Monoamine oxidase-B inhibitor[2] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 36% |
Protein binding | 88 – 94% |
Metabolism | Liver (CYP1A2-mediated) |
Elimination half-life | 3 hours[citation needed] |
Excretion | Kidney and fecal |
Identifiers | |
| |
Chemical and physical data | |
Formula | C12H13N |
Molar mass | 171.243 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Common side effects include joint pain, indigestion, depression, trouble sleeping, swelling, and nausea.[3] Other side effects may include high blood pressure, serotonin syndrome, sleepiness, compulsive gambling, and hallucinations.[3] Safety in pregnancy and breastfeeding is unclear.[4] It is an irreversible inhibitor of monoamine oxidase-B.[2]
Rasagiline was developed in the early 1979 and approved for medical use in Europe in 2005 and the United States in 2006.[5][2][6] It is available as a generic medication.[7] In the United Kingdom 4 weeks of medication costs the NHS about £2.50.[7]